Wall Street brokerages expect bluebird bio, Inc. (NASDAQ:BLUE) to announce earnings of ($1.59) per share for the current quarter, according to Zacks. Four analysts have made estimates for bluebird bio’s earnings, with the lowest EPS estimate coming in at ($1.89) and the highest estimate coming in at ($0.91). bluebird bio posted earnings of ($2.07) per share during the same quarter last year, which indicates a positive year over year growth rate of 23.2%. The business is scheduled to issue its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that bluebird bio will report full-year earnings of ($6.77) per share for the current financial year, with EPS estimates ranging from ($7.36) to ($5.18). For the next year, analysts expect that the business will post earnings of ($7.02) per share, with EPS estimates ranging from ($7.85) to ($3.93). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for bluebird bio.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.66) by $0.07. The firm had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. bluebird bio’s revenue was up 977.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.59) EPS.

Several equities research analysts recently commented on the company. Wells Fargo & Company restated an “outperform” rating and set a $158.00 target price (up previously from $134.00) on shares of bluebird bio in a research report on Tuesday. Barclays PLC assumed coverage on bluebird bio in a research report on Wednesday. They set an “overweight” rating and a $151.00 target price on the stock. Cowen and Company restated an “outperform” rating on shares of bluebird bio in a research report on Thursday, August 31st. Wedbush restated an “outperform” rating and set a $135.00 target price (up previously from $121.00) on shares of bluebird bio in a research report on Friday, September 1st. Finally, BidaskClub upgraded bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $107.86.

In related news, insider Jeffrey T. Walsh sold 12,000 shares of the stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $125.01, for a total transaction of $1,500,120.00. Following the completion of the sale, the insider now directly owns 39,305 shares of the company’s stock, valued at $4,913,518.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Lynch sold 4,000 shares of the stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $109.09, for a total value of $436,360.00. Following the sale, the director now directly owns 4,808 shares of the company’s stock, valued at $524,504.72. The disclosure for this sale can be found here. Insiders have sold 142,348 shares of company stock valued at $16,331,428 over the last ninety days. 3.90% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. QS Investors LLC increased its position in shares of bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 500 shares during the last quarter. Bank of Montreal Can increased its position in shares of bluebird bio by 118.9% during the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after acquiring an additional 911 shares during the last quarter. Turner Investments LLC purchased a new stake in shares of bluebird bio during the second quarter valued at approximately $184,000. SG Americas Securities LLC increased its position in shares of bluebird bio by 17.9% during the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 295 shares during the last quarter. Finally, Fairfield Bush & CO. purchased a new stake in shares of bluebird bio during the second quarter valued at approximately $210,000.

WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/07/brokerages-expect-bluebird-bio-inc-blue-to-announce-1-59-earnings-per-share.html.

bluebird bio (NASDAQ:BLUE) traded up 2.13% during trading on Thursday, reaching $129.20. The company had a trading volume of 895,517 shares. The firm’s market capitalization is $5.89 billion. The firm’s 50 day moving average price is $101.06 and its 200 day moving average price is $94.37. bluebird bio has a 12-month low of $37.05 and a 12-month high of $133.10.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Get a free copy of the Zacks research report on bluebird bio (BLUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.